Traders Buy Large Volume of Put Options on Endo International (ENDP)

Share on StockTwits

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) was the recipient of unusually large options trading activity on Thursday. Traders purchased 25,963 put options on the company. This is an increase of 1,227% compared to the average volume of 1,957 put options.

A number of research firms have issued reports on ENDP. ValuEngine downgraded shares of Endo International from a “buy” rating to a “hold” rating in a report on Tuesday. Cantor Fitzgerald set a $12.00 target price on Endo International and gave the stock a “hold” rating in a research note on Wednesday, August 8th. Citigroup lifted their target price on Endo International from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. Stifel Nicolaus lifted their target price on Endo International from $10.00 to $17.00 and gave the stock a “hold” rating in a research note on Thursday, August 9th. Finally, Leerink Swann lifted their target price on Endo International from $12.00 to $18.00 and gave the stock a “market perform” rating in a research note on Thursday, August 9th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $13.60.

In other Endo International news, Director Roger H. Kimmel sold 26,074 shares of Endo International stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total transaction of $414,576.60. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.80% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its stake in Endo International by 518.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 3,293,567 shares of the company’s stock valued at $19,564,000 after acquiring an additional 2,761,216 shares during the period. Bank of New York Mellon Corp raised its stake in Endo International by 13.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock valued at $23,074,000 after acquiring an additional 284,599 shares during the period. Diamond Hill Capital Management Inc. raised its stake in Endo International by 1.0% in the 2nd quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock valued at $10,375,000 after acquiring an additional 10,600 shares during the period. Schroder Investment Management Group raised its stake in Endo International by 78.1% in the 2nd quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock valued at $7,349,000 after acquiring an additional 327,775 shares during the period. Finally, River & Mercantile Asset Management LLP raised its stake in Endo International by 18.6% in the 2nd quarter. River & Mercantile Asset Management LLP now owns 554,835 shares of the company’s stock valued at $5,229,000 after acquiring an additional 87,102 shares during the period. Institutional investors and hedge funds own 98.43% of the company’s stock.

Shares of Endo International stock opened at $16.01 on Friday. Endo International has a 52-week low of $5.27 and a 52-week high of $17.46. The stock has a market capitalization of $3.80 billion, a P/E ratio of 4.17, a PEG ratio of 3.26 and a beta of 0.74. The company has a current ratio of 1.07, a quick ratio of 0.91 and a debt-to-equity ratio of -132.64.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Wednesday, August 8th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.22. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The business had revenue of $714.70 million for the quarter, compared to analysts’ expectations of $679.72 million. During the same period in the previous year, the business posted $0.93 EPS. The firm’s quarterly revenue was down 18.4% compared to the same quarter last year. sell-side analysts forecast that Endo International will post 2.6 EPS for the current year.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Read More: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply